861 related articles for article (PubMed ID: 26210353)
21. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
22. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression.
Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS
Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276
[TBL] [Abstract][Full Text] [Related]
24. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
25. Context Matters: Distinct Disease Outcomes as a Result of Crebbp Hemizygosity in Different Mouse Bone Marrow Compartments.
Zhou T; Perez SN; Cheng Z; Kinney MC; Lemieux ME; Scott LM; Rebel VI
PLoS One; 2016; 11(7):e0158649. PubMed ID: 27427906
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH.
Oliveira FM; Lucena-Araujo AR; Favarin Mdo C; Palma PV; Rego EM; Falcão RP; Covas DT; Fontes AM
Exp Hematol; 2013 Feb; 41(2):198-208. PubMed ID: 23092930
[TBL] [Abstract][Full Text] [Related]
27. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
28. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
[TBL] [Abstract][Full Text] [Related]
29. De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.
Lopes MR; Pereira JK; de Melo Campos P; Machado-Neto JA; Traina F; Saad ST; Favaro P
Sci Rep; 2017 Jan; 7():40707. PubMed ID: 28084439
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.
Navas T; Zhou L; Estes M; Haghnazari E; Nguyen AN; Mo Y; Pahanish P; Mohindru M; Cao T; Higgins LS; Platanias LC; List A; Verma A; Bhagat T; Gajavelli S; Kambhampati S
Leuk Lymphoma; 2008 Oct; 49(10):1963-75. PubMed ID: 18949619
[TBL] [Abstract][Full Text] [Related]
31. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes.
Kim M; Hwang S; Park K; Kim SY; Lee YK; Lee DS
PLoS One; 2015; 10(3):e0120602. PubMed ID: 25803272
[TBL] [Abstract][Full Text] [Related]
33. In Vitro Insights Into the Influence of Marrow Mesodermal/Mesenchymal Progenitor Cells on Acute Myelogenous Leukemia and Myelodysplastic Syndromes.
Liesveld J; Galipeau J
Stem Cells; 2023 Sep; 41(9):823-836. PubMed ID: 37348128
[TBL] [Abstract][Full Text] [Related]
34. Uncoding the genetic heterogeneity of myelodysplastic syndrome.
Lindsley RC
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):447-452. PubMed ID: 29222292
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.
Medyouf H; Mossner M; Jann JC; Nolte F; Raffel S; Herrmann C; Lier A; Eisen C; Nowak V; Zens B; Müdder K; Klein C; Obländer J; Fey S; Vogler J; Fabarius A; Riedl E; Roehl H; Kohlmann A; Staller M; Haferlach C; Müller N; John T; Platzbecker U; Metzgeroth G; Hofmann WK; Trumpp A; Nowak D
Cell Stem Cell; 2014 Jun; 14(6):824-37. PubMed ID: 24704494
[TBL] [Abstract][Full Text] [Related]
36. Myelodysplasia is in the niche: novel concepts and emerging therapies.
Bulycheva E; Rauner M; Medyouf H; Theurl I; Bornhäuser M; Hofbauer LC; Platzbecker U
Leukemia; 2015 Feb; 29(2):259-68. PubMed ID: 25394715
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathology of myelodysplastic syndromes: biology of medullary stromal and hematopoietic cells (review).
Kitagawa M; Kurata M; Yamamoto K; Abe S; Suzuki S; Umeda S
Mol Med Rep; 2011; 4(4):591-6. PubMed ID: 21584497
[TBL] [Abstract][Full Text] [Related]
38. In vitro study of biological characteristics of mesenchymal stem cells in patients with low-risk myelodysplastic syndrome.
Zhang YZ; Zhao DD; Han XP; Jin HJ; Da WM; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):813-8. PubMed ID: 18718067
[TBL] [Abstract][Full Text] [Related]
39. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
Rajapaksa R; Ginzton N; Rott LS; Greenberg PL
Blood; 1996 Dec; 88(11):4275-87. PubMed ID: 8943864
[TBL] [Abstract][Full Text] [Related]
40. Gene stage-specific expression in the microenvironment of pediatric myelodysplastic syndromes.
Roela RA; Carraro DM; Brentani HP; Kaiano JH; Simão DF; Guarnieiro R; Lopes LF; Borojevic R; Brentani MM
Leuk Res; 2007 May; 31(5):579-89. PubMed ID: 17092558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]